Showing 1–25 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Lin KY, Sun HY, Yang CJ, Lu PL, Lee YT, et al.
…erience with combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor-containing antiretroviral therapy (ART) in management of latent tuberculous infection (LTBI) is limited among people with human immunodeficiency virus (PWH). Methods From …
Wolfe A, Jadhav P, May A, Seymour S, Blanchard A, et al.
…d with each regimen. Overall, rifampin-containing shortened regimens are the preferred modality for LTBI treatment. A recent study in 2023 evaluated adherence and tolerance of the isoniazid(INH) + rifapentine(RPT), or "3HP" regimen and identified patient groups that may be at hig…
Wheeler C, Mohle-Boetani J
…16%) than among nonincarcerated persons (6%). We compared 2 regimens to treat LTBI in an adult prison population in California: 9 months of twice-weekly isoniazid (9H; previous standard of care) and 12 once-weekly doses of isoniazid and rifapentine (3HP; introduced in 2011). Meth…
Gao L, Zhang H, Xin H, Liu J, Pan S, et al.
… Registry identifier ChiCTR-IOR-15007202), two short-course regimens with rifapentine plus isoniazid (a 3-month once-weekly regimen and a 2-month twice-weekly regimen) were initially designed to be evaluated for rural residents aged 50-69 years with LTBI in China.Due to the incre…
Mark Kosenko, Lilit Davtian, Ekaterina Iakovleva, Mukhammad Ashurov, Dmitrii Podgalo, et al.
…onths of isoniazid (9H) versus shorter rifamycin-containing regimens for treating latent tuberculosis infection (TBI) in children. **METHODS:** We systematically searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials to June 2025 for randomized, controlled …
Doan TN, Fox GJ, Meehan MT, Scott N, Ragonnet R, et al.
…erefore LTBI treatment is key for TB elimination. Treatment regimens for LTBI include self-administered daily isoniazid for 6 (6H) or 9 (9H) months, self-administered daily rifampicin plus isoniazid for 3 months (3RH), self-administered daily rifampicin for 4 months (4R) and week…
Villa S, Ferrarese M, Sotgiu G, Castellotti PF, Saderi L, et al.
…either isoniazid (INH) alone or rifampicin (RIF)-containing regimens. This study aims to assess and compare PT completion rates, the occurrence of adverse events, and the time of dropout among those receiving INH-alone or RIF-containing regimens at Villa Marelli Institute, Milan,…
Feng PI, Horne DJ, Wortham JM, Katz DJ
… for Disease Control and Prevention has recommended shorter regimens-12 weeks of isoniazid and rifapentine or 4 months of rifampin-because they have similar efficacy, better tolerability, and higher treatment completion than 6-9 months of isoniazid. The objective of this analysis…
Pangprasertkul S, Buawangpong N, Pinyopornpanish K, Jiraporncharoen W, Angkurawaranon C
Background Children and adolescents are at increased risk of progressing from latent to active tuberculosis (TB). The 3-month, once-weekly isoniazid and rifapentine (3HP) regimen offers a shorter tuberculosis preventive treatment (TPT) option. However, evidence regarding its comp…
Joana Marques Simões, Dalila Ferreira, Teresa Mourato, Ana Pais, André Dias, et al.
… of adverse events. The shorter duration of rifamycin-based regimens has become increasingly preferable. The one month of daily rifapentine plus isoniazid (1HP) has demonstrated low toxicity and higher completion rates in HIV-infected populations. This study aims to compare the c…
Shahid NUA, Naguit N, Jakkoju R, Laeeq S, Reghefaoui T, et al.
…he effectiveness, safety, and completion of any of the five regimens available for latent tuberculosis infection. These options are the most classic and standard nine months of isoniazid given daily, which is now more commonly given as six months course, three months of daily iso…
Hualin Jiang, Rui Li, Tianhua Zhang, Qinghu Wang, Haini Liu, et al.
…ss ratios (ICER) of this optimal TPT strategy with five TPT regimens (isoniazid monotherapy with two different durations, rifampin monotherapy, and combinations of isoniazid with rifampin or rifapentine) over 2025-2050, compared with no TPT, from a health system perspective. A wi…
Peng TR, Chen JH, Chang YH, Shiang JC, Lee MC, et al.
… incident tuberculosis or the completion rates of treatment regimens were included. The Cochrane Collaboration tool was used to assess the risk of bias. We tested for possible global inconsistency with a χ 2 test and local inconsistency by calculating inconsistency factors for ea…
Surey J, Stagg HR, Yates TA, Lipman M, White PJ, et al.
…(LTBI) to prevent future cases. Promising trials of shorter regimens have shown them to be effective as preventative TB treatment, however there is a paucity of data on self-administered treatment completion rates. This pilot trial assessed treatment completion, adherence, safety…
Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, et al.
…that 3HP is as safe and effective as other recommended LTBI regimens and achieves substantially higher treatment completion rates. In July 2017, the Work Group presented the meta-analysis findings to a group of TB experts, and in December 2017, CDC solicited input from the Adviso…
Cao X, Guo T, Xin H, Du J, Yang C, et al.
Purpose Several model studies suggested the implementation of latent tuberculosis infection (LTBI) testing and treatment could greatly reduce the incidence of tuberculosis (TB) and achieve the 2035 target of the "End TB" Strategy in China. The present study aimed to evaluate the …
Rangaka MX, Hamada Y, Duong T, Bern H, Calvert J, et al.
…ises its therapeutic effectiveness. Novel rifapentine-based regimens and treatment support based on behavioural science theory may improve treatment adherence and completion. Methods and analysis A pragmatic multicentre, open-label, randomised controlled trial assessing the effec…
Sabella-Jiménez V, Hoyos Mendez Y, Benjumea-Bedoya D, Estupiñán-Bohorquez AF, Acosta-Reyes J, et al.
…ge. Alternatives to isoniazid, such as rifamycin containing regimens, should be considered for prophylaxis. Previous systematic reviews, with different study designs and data combining results on children and adults, have evaluated the comparative efficacy and harms of LTBI treat…
Apriani L, Koesoemadinata RC, Bastos ML, Wulandari DA, Santoso P, et al.
BACKGROUND: The implementation of tuberculosis preventive treatment (TPT) is challenging especially in resource-limited settings. As part of a Phase 3 trial on TPT, we described our experience with the use of rifampicin for 4 months (4R) and isoniazid for 9 months (9H) in Indones…
Macaraig MM, Jalees M, Lam C, Burzynski J
…ectiveness of preferentially offering two shorter treatment regimens-4 months of daily rifampin (4R) and 3 months of once-weekly isoniazid and rifapentine (3HP)-as an alternative to 9 months of daily isoniazid (9H) for the treatment of latent tuberculous infection (LTBI). Design …
Lin SY, Feng JY, Lee CY, Lin YC, Chou YH, et al.
Although patients with end-stage renal disease receiving maintenance hemodialysis are at high risk for tuberculosis, the optimal treatment regimen for latent tuberculosis infection (LTBI) in this group has scarcely been studied for predictors of completion rate and adverse drug e…
Alvarez GG, Sullivan K, Pease C, Van Dyk D, Mallick R, et al.
… 2016, 3HP was offered as an alternative to standard clinic regimens which included 9 months of daily isoniazid or 4 months of daily rifampin. The primary outcome was the proportion of patients who completed TPT among all patients who started treatment. Using segmented autoregres…
Xin H, Cao X, Zhang H, Feng B, Du Y, et al.
Background Enlarging tuberculosis (TB) preventive treatment among at-risk populations is a critical component of the End TB Strategy. There is an urgent need to develop suitable latent tuberculosis infection (LTBI) testing and treatment tools according to the local TB epidemic an…
Santin M, Perez-Recio S, Grijota MD, Anibarro L, Barcala JM, et al.
…the study is to evaluate three short-course rifamycin-based regimens for the treatment of latent TB in ESKD patients. Methods Study design and setting. This is a prospective, open label, randomized clinical trial, that will be conducted at seven teaching hospitals in Spain. Study…
Simkins J, Donato-Santana C, Morris MI, Abbo LM, Camargo JF, et al.
…T-GIT-positive and QFT-GIT-negative donors. We assessed the regimens used to treat LTBI and whether the recipients of QFT-GIT-positive donors developed active tuberculosis (TB). Results Forty out of 427 (9%) potential living kidney donors had a positive QFT-GIT. QFT-GIT-positive …